BIOA

Vorhandelsmarkt: 4.80 0.04 +0.84%

Bioage Labs Inc (BIOA)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Bioage Labs Inc Stock (BIOA) Company Profile

Bioage Labs Inc

Healthcare (1161)

510-806-1445

1445A SOUTH 50TH STREET, RICHMOND

Nächster Verdiensttermin

Neueste SEC-Einreichungen

BIOA's Discussions on Twitter

Vergleichen Sie BIOA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BIOA Bioage Labs Inc	4.76	162.04M	0	0	0	0.00
ZTS Zoetis Inc	151.19	68.05B	9.29B	2.52B	2.28B	5.57
TAK Takeda Pharmaceutical Co Adr	14.55	46.58B	30.08B	710.16M	4.45B	0.2182
HLN Haleon Plc Adr	9.65	43.71B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.29	18.40B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	297.89	13.23B	2.99B	1.21B	1.13B	25.06

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-28	Eingeleitet	William Blair	Mkt Perform
2024-12-10	Herabstufung	Morgan Stanley	Overweight → Underweight
2024-12-09	Herabstufung	Citigroup	Buy → Neutral
2024-12-09	Herabstufung	Jefferies	Buy → Hold
2024-10-21	Eingeleitet	Citigroup	Buy
2024-10-21	Eingeleitet	Jefferies	Buy
2024-10-21	Eingeleitet	Morgan Stanley	Overweight

Alle ansehen

Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten

Finanzdaten der Bioage Labs Inc-Aktie (BIOA)

Es liegen keine Finanzdaten für Bioage Labs Inc (BIOA) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Bioage Labs Inc (BIOA)

Bioage Labs Inc Stock (BIOA) Company Profile

Vergleichen Sie BIOA mit anderen Aktien

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten

What drives BioAge Labs Inc. stock priceRapid capital growth - jammulinksnews.com

What analysts say about BioAge Labs Inc. stockUnprecedented market success - jammulinksnews.com

BioAge Labs Inc. Stock Analysis and ForecastRapidly expanding wealth - Autocar Professional

Is BioAge Labs Inc. a good long term investmentMassive stock growth - Autocar Professional

BIOA ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by BioAge Labs, Inc. - ACCESS Newswire

Is BioAge Labs (NASDAQ:BIOA) Weighed On By Its Debt Load? - simplywall.st

What makes BioAge Labs Inc. stock price move sharplyMarket Trend Watch - Newser

Drugmaker Fights Claims Over 'Misleading' IPO Statements - Law360

Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO - MSN

BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire

Levi & Korsinsky Announces an Investigation on Behalf of BioAge Labs, Inc. (BIOA) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire

BioAge Labs, Inc.(NasdaqGS: BIOA) dropped from Russell 3000 Growth Index - MarketScreener

Bronstein, Gewirtz & Grossman, LLC Is Investigating BioAge Labs, Inc. (BIOA) And Encourages Shareholders to Connect - ACCESS Newswire

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions - The Manila Times

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs - ACCESS Newswire

BioAge to analyze 17,000 HUNT Biobank samples for aging research By Investing.com - Investing.com Nigeria

BioAge Labs to Profile Norwegian Biobank for Aging Drug Discovery - MarketScreener

BioAge Labs expands drug discovery platform with data from HUNT Biobank - TipRanks

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank - Yahoo Finance

BioAge to analyze 17,000 HUNT Biobank samples for aging research - Investing.com Australia

BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review - marketscreener.com

Healthcare companies chase cures and capital in South Florida - Sun Sentinel

An Investigation Has Commenced on Behalf of BioAge Labs, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your BIOA Losses. - ACCESS Newswire

BioAge Labs Elects Directors at Annual Meeting - TipRanks

BIOA CLASS ACTION ALERT: BioAge Labs's 76% Stock Drop Triggers Securities Fraud Class Action; Contact BFA Law before March 10 Deadline - ACCESS Newswire

Lead Plaintiff Appointed in BioAge Labs Class Action — Here’s How You Can Recover Your Losses - TradingView

BioAge Labs, Inc. Announces Updates on APJ Agonist Program Updates - marketscreener.com

BioAge Labs Updates Milestones for NLRP3 Program - TipRanks

Bioage advances apelin receptor agonist program with option to Jikang’s nanobody - BioWorld MedTech

BioAge deepens weight loss R&D with fresh apelin receptor push - The Pharma Letter

BioAge Labs expands APJ agonist pipeline with biologic candidates - TipRanks

BioAge Labs Enters Option Agreement with JiKang Therapeutics to In-License Novel APJ Agonist Antibody and Expands Intellectual Property for Small Molecule APJ Agonists - Nasdaq

BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates - The Manila Times

Breakthrough Obesity Drug Pipeline: BioAge's New Treatment Doubles GLP-1 Weight Loss Effect - Stock Titan

Analysts Offer Insights on Healthcare Companies: Talkspace (TALK) and BioAge Labs, Inc. (BIOA) - The Globe and Mail

Bioage plans mid-year IND submission for BGE-102 for obesity - BioWorld MedTech

BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic - Pipelinereview

BioAge advances obesity drug into clinical trials By Investing.com - Investing.com South Africa

BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 - Insider Monkey

Jefferies maintains hold on BioAge Labs with $4 target By Investing.com - Investing.com India

Jefferies maintains hold on BioAge Labs with $4 target - Investing.com

BioAge Labs, Inc. Completes IND-enabling Studies for BGE-102 - marketscreener.com

BioAge advances obesity drug into clinical trials - Investing.com Australia

BioAge Labs completes IND-enabling studies for BGE-102, a - GlobeNewswire

Finanzdaten der Bioage Labs Inc-Aktie (BIOA)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie BIOA